

### IPO Expected Timetable#

| Stock Code | Stock Name | Application lists close | Allotment Date | Listing Date |
|------------|------------|-------------------------|----------------|--------------|
| 06979      | ZJLD       | 2023/04/20              | 2023/04/26     | 2023/04/27   |
| 02415      | MEDSCI     | 2023/04/20              | 2023/04/26     | 2023/04/27   |

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit [www.cfsg.com.hk](http://www.cfsg.com.hk) or contact our account executives or customer service officers

### Subscription Details via CASH Securities

#### ZJLD (06979)

|                                     |                         |
|-------------------------------------|-------------------------|
| Offer Period                        | 2023/04/17 - 2023/04/20 |
| Closing Time for Margin Application | N/A                     |
| Subscription Fee                    | N/A                     |
| Days For Margin Financing           | N/A                     |
| Indicative Interest Rate            | N/A                     |

\*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.

#### MEDSCI (02415)

|                                     |                         |
|-------------------------------------|-------------------------|
| Offer Period                        | 2023/04/17 - 2023/04/20 |
| Closing Time for Margin Application | N/A                     |
| Subscription Fee                    | N/A                     |
| Days For Margin Financing           | N/A                     |
| Indicative Interest Rate            | N/A                     |

\*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.

### ZJLD Group Inc (6979.HK)

#### Share Offer Highlights

|                                 |  |
|---------------------------------|--|
| Total Number of Offer Shares:   | 490,699,800 Shares (subject to the Overallotment Option)                   |
| -Number of Public Offer Shares: | 49,070,000 Shares (subject to reallocation)                                |
| -Number of Placing Shares:      | 441,629,800 Shares (subject to reallocation and the Over-allotment Option) |
| Number of Shares per Lot:       | 200 Shares   |
| Offer Price:                    | HKD 10.78-12.98 per Share  |
| 2020 Historical P/E ratio:      | 29.99x-36.11x  |
| Sponsor:                        | Goldman Sachs 、 CHINA SECURITIES INTERNATIONAL                             |

#### Company Overview

This company is a baijiu company in China devoted to offering premium baijiu products featuring sauce aroma profile. According to Frost & Sullivan, it ranked 14th among all baijiu companies in China with a market share of 0.8%, in terms of revenue in 2021. It has grown significantly faster than the industry average during the Track Record Period. Its growth capitalized on the increasing popularity of sauce aroma baijiu across China and consumer preferences towards premiumization, and it is expected to continue to benefit from these market trends. It operates four major baijiu brands in China, including its flagship brand Zhen Jiu (珍酒), a thriving brand Li Du (李渡), as well as two regional leading brands Xiang Jiao (湘窖) and Kai Kou Xiao (開口笑). Leveraging these renowned brands, it promotes traditional Chinese baijiu culture by developing a broad selection of fragrant, mellow baijiu products to appeal to different consumer preferences and capture broader market opportunities.

For the year ended December 31, 2020, 2021 and 2022, the Company's net profits were RMB520.09mn , RMB 1,032.20mn and RMB 1,029.87 mn respectively.

## MedSci Healthcare Holdings Limited (2415.HK)

### Share Offer Highlights

|                                 |   |
|---------------------------------|---|
| Total Number of Offer Shares:   | 66,789,000 Shares (subject to the Over-allotment Option)                  |
| -Number of Public Offer Shares: | 6,679,000 Shares (subject to reallocation)                                |
| -Number of Placing Shares:      | 60,110,000 Shares (subject to reallocation and the Over-allotment Option) |
| Number of Shares per Lot:       | 250 Shares  |
| Offer Price:                    | HKD 9.10-10.16 per Share  |
| 2020 Historical P/E ratio:      | -   |
| Sponsor:                        | CICC、MACQUARIE  |

### Company Overview

This company operates online professional physician platforms in China. As of December 31, 2022, its platform had approximately 2.9 million registered physician users and its average MAU reached approximately 2.7 million in 2022. As illustrated by the diagram below, it mainly provides physician platform solutions, precision omni-channel marketing solutions and RWS solutions to its customers. It believes such solution offerings can help generate and share meaningful medical evidence to a wider physician community and help guide prescription decisions of physicians in order to promote the rational use of medical products and deliver better value and care to patients. It is committed to solidifying its position as a platform-based, professional-knowledge-oriented and digitalized med-tech company and aspire to enhance the overall quality of patients' healthcare through the value offered by generating and sharing medical evidence.

For the year ended December 31, 2020, 2021 and 2022, the Company's net profits(losses) were RMB28.91mn, RMB (151.03)mn and RMB (99.88) mn respectively.

### Source

IPO Prospectus

### Contact Us

|                           |  |                    |
|---------------------------|--|--------------------|
| Headquarters:             | 22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong  | (852) 2287 8788    |
| Wealth Management Centre: | 1001B, 10/F, Tower 535 Jaffe Road Causeway Bay, Hong Kong  | (852) 2287 8788    |
| HK Services Centre:       | 6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon   | (852) 2748 0110    |
| China Services Centre:    | 1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen                                   | (86-755) 2216 5888 |
|                           | 2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai | (86-21) 3227 9888  |
|                           | Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He District, Guangzhou                | (86-20) 8981 7463  |

### Declaration:

The above information is provided and distributed by CASH Financial Services Group Limited ( "CASH" ). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.